149 related articles for article (PubMed ID: 36331867)
21. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
22. Artificial intelligence for tumour tissue detection and histological regression grading in oesophageal adenocarcinomas: a retrospective algorithm development and validation study.
Tolkach Y; Wolgast LM; Damanakis A; Pryalukhin A; Schallenberg S; Hulla W; Eich ML; Schroeder W; Mukhopadhyay A; Fuchs M; Klein S; Bruns C; Büttner R; Gebauer F; Schömig-Markiefka B; Quaas A
Lancet Digit Health; 2023 May; 5(5):e265-e275. PubMed ID: 37100542
[TBL] [Abstract][Full Text] [Related]
23. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarcinoma.
Shoucair S; Chen J; Martinson JR; Habib JR; Kinny-Köster B; Pu N; van Oosten AF; Javed AA; Shin EJ; Ali SZ; Lafaro KJ; Wolfgang CL; He J; Yu J
JAMA Surg; 2022 Jul; 157(7):e221362. PubMed ID: 35612832
[TBL] [Abstract][Full Text] [Related]
24. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy.
Janssen BV; Tutucu F; van Roessel S; Adsay V; Basturk O; Campbell F; Doglioni C; Esposito I; Feakins R; Fukushima N; Gill AJ; Hruban RH; Kaplan J; Koerkamp BG; Hong SM; Krasinskas A; Luchini C; Offerhaus J; Sarasqueta AF; Shi C; Singhi A; Stoop TF; Soer EC; Thompson E; van Tienhoven G; Velthuysen MF; Wilmink JW; Besselink MG; Brosens LAA; Wang H; Verbeke CS; Verheij J;
Mod Pathol; 2021 Jan; 34(1):4-12. PubMed ID: 33041332
[TBL] [Abstract][Full Text] [Related]
25. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
[TBL] [Abstract][Full Text] [Related]
26. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia.
Horn LC; Reichert A; Oster A; Arndal SF; Trunk MJ; Ridder R; Rassmussen OF; Bjelkenkrantz K; Christiansen P; Eck M; Lorey T; Skovlund VR; Ruediger T; Schneider V; Schmidt D
Am J Surg Pathol; 2008 Apr; 32(4):502-12. PubMed ID: 18223479
[TBL] [Abstract][Full Text] [Related]
27. Interobserver Variability in Assessment of Depth of Submucosal Invasion for Colonic Endoscopic Resections Among Subspecialized Gastrointestinal Pathologists.
Karamchandani DM; Westerhoff M; Arnold CA; Gonzalez RS; Westbrook LM; Goetz L; King TS; Panarelli NC
Arch Pathol Lab Med; 2022 May; 147(5):534-545. PubMed ID: 35943856
[TBL] [Abstract][Full Text] [Related]
28. Interobserver agreement and accuracy of preoperative endoscopic ultrasound-guided biopsy for histological grading of pancreatic cancer.
Larghi A; Correale L; Ricci R; Abdulkader I; Monges G; Iglesias-Garcia J; Giovannini M; Attili F; Vitale G; Hassan C; Costamagna G; Rindi G
Endoscopy; 2015 Apr; 47(4):308-14. PubMed ID: 25521572
[TBL] [Abstract][Full Text] [Related]
29. Interobserver Variability in Scoring Liver Biopsies with a Diagnosis of Alcoholic Hepatitis.
Horvath B; Allende D; Xie H; Guirguis J; Jeung J; Lapinski J; Patil D; McCullough AJ; Dasarathy S; Liu X
Alcohol Clin Exp Res; 2017 Sep; 41(9):1568-1573. PubMed ID: 28654190
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma.
Rykina-Tameeva N; Nahm CB; Mehta S; Gill AJ; Samra JS; Mittal A
HPB (Oxford); 2020 Nov; 22(11):1631-1636. PubMed ID: 32247587
[TBL] [Abstract][Full Text] [Related]
31. Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?
Yang P; Mao K; Gao Y; Wang Z; Wang J; Chen Y; Ma C; Bian Y; Shao C; Lu J
Cancer Imaging; 2023 Jan; 23(1):8. PubMed ID: 36653861
[TBL] [Abstract][Full Text] [Related]
32. Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications.
Cacciato Insilla A; Vivaldi C; Giordano M; Vasile E; Cappelli C; Kauffmann E; Napoli N; Falcone A; Boggi U; Campani D
Front Oncol; 2020; 10():64. PubMed ID: 32117724
[TBL] [Abstract][Full Text] [Related]
33. Deep Learning for Predicting Effect of Neoadjuvant Therapies in Non-Small Cell Lung Carcinomas With Histologic Images.
Terada K; Yoshizawa A; Liu X; Ito H; Hamaji M; Menju T; Date H; Bise R; Haga H
Mod Pathol; 2023 Nov; 36(11):100302. PubMed ID: 37580019
[TBL] [Abstract][Full Text] [Related]
34. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
[TBL] [Abstract][Full Text] [Related]
35. Interobserver Variability and Challenges in Intraoperative Frozen Section Evaluation of Pancreatic Margins in Pancreatectomy Specimens.
Dhingra S; Taggart MW; Foo WC; Rashid A; Heredia MLM; May SB; Van Buren G; Fisher WE; Wang H
Ann Clin Lab Sci; 2023 Nov; 53(6):847-860. PubMed ID: 38182140
[TBL] [Abstract][Full Text] [Related]
36. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.
Wang H; Chetty R; Hosseini M; Allende DS; Esposito I; Matsuda Y; Deshpande V; Shi J; Dhall D; Jang KT; Kim GE; Luchini C; Graham RP; Reid MD; Basturk O; Hruban RH; Krasinskas A; Klimstra DS; Adsay V;
Am J Surg Pathol; 2022 Jun; 46(6):754-764. PubMed ID: 34889852
[TBL] [Abstract][Full Text] [Related]
37. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
38. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
Nagaria TS; Wang H; Chatterjee D; Wang H
Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
[TBL] [Abstract][Full Text] [Related]
39. Rectal cancer staging post neoadjuvant therapy--how should the changes be assessed?
Bateman AC; Jaynes E; Bateman AR
Histopathology; 2009 May; 54(6):713-21. PubMed ID: 19438746
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
